Alcon Shareholders Reject Novartis Offer As Inadequate
This article was originally published in The Gray Sheet
Executive Summary
When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52% stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23%, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders.
You may also be interested in...
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company
Alcon To Launch LenSx Cataract Surgery Laser In Q4 Following Acquisition
Alcon will launch a femtosecond laser system for cataract surgery in the fourth quarter after acquiring technology developer LenSx Lasers